Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells

Clinical and Experimental Rheumatology

Volumn 27, Issue 1, 2009, Pages 99-107

  Kolar, Paula ^a   Lach, Steffen ^a   Gaber, Timo ^a,b   Maschmeyer, Patrick ^a   Dziurla, René ^a   Tripmacher, Robert ^a   Krocker, Dörte ^a   Matziolis, Georg ^a   Perka, Carsten ^a   Burmester, Gerd Rüdiger ^a   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

Author keywords

Celecoxib; Cell viability; Glucose transporter 1; Hypoxia inducible factor 1 ; Osteoblasts; Osteoprotegerin; Oxygen consumption

Indexed keywords

7AAD; CELECOXIB; CELL MARKER; DEXAMETHASONE; DIMETHYL SULFOXIDE; DYE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOCORTIN 5; MESSENGER RNA; OSTEOPROTEGERIN; TRYPAN BLUE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE REMODELING; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SAFETY; ENERGY METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OSTEOBLAST; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; OSTEOBLASTS; OSTEOPROTEGERIN; PYRAZOLES; SULFONAMIDES;

EID: 63049128310     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. SIBILIA J, SORDET C, MRABET D, WACHSMANN D: [Understanding rheumatoid arthritisc]. Rev Prat 2005; 55: 2134-42.
2. BROSCH S, REDLICH K, PIETSCHMANN P: [Pathogenesis of osteoporosis in rheumatoid arthritisc]. Acta Med Austriaca 2003; 30: 1-5.
3. IGARASHI K, WOO JT, STERN PH: Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. Biochern Pharmacol 2002; 63: 523-32.
4. DEEKS JJ, SMITH LA, BRADLEY MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002; 325: 619.
5. WANDERS A, HEIJDE D, LANDEWE R et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005; 52: 1756-65.
6. NEAL B, RODGERS A, DUNN L, FRANSEN M: Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst 2000 Rev: CD001160.
7. VAN DER HEIDE HJ, KOOREVAAR RC, LEMMENS JA, VAN KAMPEN A, SCHREURS BW: Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 2007; 127: 557-61.
8. VAN DER HEIDE HJ, RUNBERG WJ, VAN SORGE A, VAN KAMPEN A, SCHREURS BW: Similar effects of rofecoxib and indomethacin on the incidence ofheterotopic ossification after hip arthroplasty. Acta Orthop 2007; 78: 90-4.
9. SIMONET WS,ALACEY DL, DUNSTAN CR et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
10. YASUDA H, SHIMA N, NAKAGAWA N et al.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-37.
11. THEOLEYRE S, WITTRANT Y, TAT SK, FORTUN Y, REDINI F, HEYMANN D: The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004; 15: 457-75.
12. HOFBAUER LC, GORI F, RIGGS BL et al.: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic line-age cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-9.
13. VIDAL NO, BRANDSTROM H, JONSSON KB, OHLSSON C: Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol 1998; 159: 191-5.
14. KRAUSE MM, BRAND MD, KRAUSS S et al.: Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum 2003; 48: 1438-44.
15. CAPARROZ-ASSEF SM, SALGUEIRO-PAGADIGORRIA CL, BERSANI-AMADO CA, BRACHT A, KELMER-BRACHT AM, ISHII-IWAMATO EL: The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulfide in liver mitochondria from adjuvant induced arthritic rats. Cell Biochem Funct 2001; 19: 117-24.
16. PETRESCU I, TARBA C: Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochem Biophys Acta 1997; 1318: 385-94.
17. JACOB M, BJARNASON I, RAFI S, WRIGGLES-WORTH J, SIMPSON RJ: A study of the effects of indometacin on liver mitochondria from rats, mice and humans. Aliment Pharmacol Ther 2001; 15: 1837-42.
18. TIBBLE JA, SIGHTHORSSON G, FOSTER R, BJARNASON I: Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000; 35: 802-7.
19. MAHMUD T, RAM SS, SCOTT DL, WRIGGLESWORTH JM, BJARNASON I: Nonsteroidal anti-inflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum 1996; 39: 1998-2003.
20. BECKER M, NEWMAN S, ISMAIL-BEIGI F: Stimulation of GLUT1 glucose transporter expression in response to inhibition of oxidative phosphorylation: Role of reduced sulfhydryl groups. Mol Cell Endocrinol 1996; 121: 165-70.
21. HAMRAHIAN AH, ZHANG JZ, ELKHAIRI FS, PRASAD R, ISMAIL-BEIGI F: Activation of Glut1 glucose transporter in response to inhibition of oxidative phosphorylation. Arch Biochem Biophys 1999; 368: 375-9.
22. ZHANG JZ, BEHROOZ A, ISMAIL-BEIGI F: Regulation of glucose transport by hypoxia. Am J Kidney Dis 1999; 34: 18 9-202.
23. GABER T, DZIURLA R, TRIPMACHER R, BURMESTER GR, BUTTGEREIT F: Hypoxia inducible factor (HIF) in rheumatology: Low O2! See what HIF can do! Ann Rheum Dis 2005; 64: 971-80.
24. STEINBACH G, LYNCH PM, PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
25. GRÖSCH S, TEGEDER I, NIEDERBERGER E, BRÄUTIGAM L, GEISSLINGER G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-4.
26. SWAMY MV, COOMA I, PATLOLLA JM, SIMI B, REDDY BS, RAO CV: Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004; 3: 215-21.
27. HEREMANS H, BILLIAU A, CASSIMAN JJ, MULIER JC, DE SOMER P: In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology 1978; 35: 246-52.
28. GUNDLE R, BERESFORD JN: The isolation and culture of cells from explants of human trabecular bone. Calcif Tissue Int 1995; 56 (Suppl. 1): S8-10.
29. SIGGELKOW H, REBENSTORFF K, KURRE W et al.: Development of the osteoblast phenotype in primary human osteoblasts in culture: Comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 1999; 75: 22-35.
30. KUHNKE A, BURMESTER GR, KRAUSS S, BUTTGEREIT F: Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann Rheum Dis 2003; 62: 133-9.
31. GOODMAN S, MA T, TRINDADE M et al.: COX-2 selective NSAID decreases bone in-growth in vivo. Orthop Res 2002; 20: 1164-9.
32. ENDO K, SAIRYO K, KOMATSUBARA S, SASA T, EGAWA H: Cyclooxygenase-2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 2002; 21: 235-8.
33. MCLAUGHLIN SG, DILGER JP: Transport of protons across membranes by weak acids. Physiol Rev 1980; 60: 825-63.
34. BEHROOZ A, ISMAIL-BEIGI F: Dual control of glutl glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem 1997; 272: 5555-62.
35. EBERT BL, FIRTH JD, RATCLIFFE PJ: Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995; 270: 29083-9.
36. ZWERINA J, HAYER S, TOHIDAST-AKRAD M et al.: Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277-90.
37. HU F, WANG X, PACE TW, WU H, MILLER AH: Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry 2005; 10: 426-8.
38. DAVIES NM, MCLACHLAN AJ, DAY RO, WILLIAMS KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225-42.
39. LEVITY RJ, POLLAK M: Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 2002; 62: 7372-6.